Overview of The Drive with Dr. Linus Abrams
In this episode, Peter Attia speaks with psychiatrist Dr. Linus Abrams about a broader model of mental health that goes beyond neurotransmitters alone. Abrams argues that psychiatry should aim not just to reduce symptoms, but to restore a fuller human experience, and he explains how hormones, thyroid function, sleep, metabolism, inflammation, stress, and circadian biology can all shape mood and cognition. The conversation also covers the strengths and limitations of standard psychiatric medications, how to distinguish bipolar from unipolar depression, and where ketamine and psychedelic therapies may fit in the future of treatment.
Main Themes and Takeaways
Psychiatry should be more than symptom reduction
- Abrams says the field often focuses on lowering symptoms, but not always on helping patients regain vitality, meaning, and quality of life.
- He sees psychiatry as deeply humanistic and existential, with medication as one tool among many.
- He emphasizes that a successful prescription can still feel incomplete if the patient feels emotionally blunted or less fully alive.
Diagnosis matters as much as medication
- A major theme is the importance of correctly identifying bipolar vs. unipolar depression.
- Misdiagnosing bipolar depression as unipolar depression and treating with antidepressants can trigger:
- hypomania
- cycling
- agitation
- mixed states
- insomnia and racing thoughts
- For bipolar depression, mood stabilizers such as lamotrigine or lithium are often more appropriate first-line choices.
Mental health is shaped by whole-body physiology
Abrams argues that psychiatric symptoms often reflect interactions among:
- hormones
- metabolism
- inflammation
- circadian rhythm and sleep
- chronic stress and hyperarousal
He sees these as interconnected systems rather than separate silos.
Psychopharmacology: What the Common Drugs Are Doing
SSRIs and SNRIs
- SSRIs primarily amplify serotonin signaling.
- SNRIs affect both serotonin and norepinephrine, and may be less likely to cause emotional blunting or cognitive dulling in some patients.
- Abrams notes that increasing serotonin can sometimes reduce dopamine and norepinephrine function, which may explain:
- feeling “better” but less energetic
- sexual side effects
- reduced motivation or “oomph”
Why “antidepressant” can be misleading
- He argues the label is too narrow because SSRIs are often used for:
- anxiety
- OCD
- PTSD
- dysthymia
- In his view, these drugs are often better thought of as signal amplifiers rather than purely “antidepressants.”
Older antidepressants
- Tricyclic antidepressants and MAO inhibitors were effective but had major drawbacks:
- more dangerous side effects
- overdose toxicity
- dietary restrictions with MAOIs
- SSRIs were a major advance largely because they were safer and better tolerated.
Hormones and Psychiatry
Estradiol
Abrams describes estradiol as a:
- constitutive
- pleiotropic
- multi-system regulator
He emphasizes that estradiol is not just a reproductive hormone; it affects brain systems involved in:
- serotonin
- dopamine
- GABA
- acetylcholine
- glutamate/NMDA signaling
He also notes that estradiol influences gene transcription and supports neuroplasticity through pathways including BDNF and neurotransmitter synthesis.
Why low estrogen can affect mood and cognition
When estrogen declines, some women experience:
- anxiety
- depression
- cognitive difficulty
- irritability
- reduced stress resilience
Abrams says severity varies widely and depends on:
- genetics
- receptor sensitivity
- life stress
- sleep
- metabolic health
- social support
- caregiving burden
Testosterone in men and women
- In men, declining testosterone can present as:
- dulling
- low motivation
- reduced reward drive
- executive dysfunction
- libido decline
- In women, testosterone is also important, especially for libido.
- He notes that many women are functionally dependent on testosterone for sexual desire, even though the absolute serum numbers look very different due to units.
Progesterone and mood
- Abrams highlights that hormone fluctuation, not just absolute levels, often drives symptoms.
- The crash in progesterone and its metabolite allopregnanolone is central to:
- PMS
- PMDD
- postpartum mood disorders
- Postpartum is especially dramatic because progesterone and estrogen drop sharply after delivery.
Thyroid function
- He stresses that many people with “normal” TSH still have functionally low thyroid activity.
- He pays close attention to:
- free T4
- free T3
- symptoms, not just TSH
- Low thyroid tends to show up as depression and low energy.
- Hyperthyroidism is more likely to look like somatic anxiety, agitation, palpitations, and insomnia.
Thyroid as a depression treatment
- For some treatment-resistant depression, he may use:
- T3
- T4 + T3 combination therapy
- He sees thyroid support as particularly useful when energy, metabolism, and drive are depressed.
Stress, Modern Life, and Mental Health
Hyperarousal as a chronic state
Abrams thinks one of the most common hidden drivers of psychiatric distress is chronic stress activation:
- caregiving burdens
- overwork
- illness
- social isolation
- poor sleep
- digital overload
He views cortisol as a signal, not the root cause:
- the body is responding to a chronic mismatch between environment and adaptive capacity.
Modernity may worsen mental health
The discussion suggests that modern life may contribute to distress through:
- social comparison
- digital isolation
- less outdoor time
- fewer real-world relationships
- less physical movement
- disrupted sleep
- reduced circadian alignment
Attia and Abrams also discuss how some mental-health problems may be “anti-normative” to modern life, meaning people may need to consciously do what used to happen naturally:
- get outdoor light
- limit screens
- protect sleep
- move more
- reduce information overload
Ketamine and Psychedelic Therapies
Ketamine
- Ketamine is an NMDA receptor antagonist that can rapidly reduce suicidal intensity and severe depressive symptoms.
- Abrams sees it mainly as a bridge treatment, not always a definitive solution.
- It is fast-acting but often temporary, and should be used with supervision.
- He is strongly concerned about recreational or unsupervised ketamine use.
Psychedelics
The conversation touches on classic psychedelics and MDMA as potentially transformative, but unpredictable.
Potential promise
- They may create a temporary window of neuroplasticity.
- This could help patients reframe maladaptive beliefs or traumatic experiences.
- Abrams is especially interested in:
- end-of-life distress
- PTSD
- highly selected patients who may benefit from a durable reset
Risks and caution
- Both Attia and Abrams describe psychedelic effects as highly variable.
- A therapeutic experience can be profound and lasting, but a bad experience can be deeply distressing.
- They caution against overgeneralizing from dramatic anecdotes or single case reports.
Personal experiences
- Attia shares both positive and very negative personal experiences with psilocybin and ketamine.
- His takeaway: these drugs can be life-changing, but they are not uniformly safe or predictable, and dose/response can be very individual.
Practical Clinical Lessons
What Abrams looks for in evaluation
- He starts by asking: “How can I help?”
- He lets patients lead the conversation rather than imposing a narrow diagnostic frame.
- He pays attention to:
- mood patterns
- sleep
- energy
- irritability vs. volatility
- cognitive symptoms
- life stress
- endocrine clues
- prior medication reactions
Medication response is diagnostically useful
- A trial of a psychotropic drug can provide important information, even if it is not the final answer.
- Side effects or paradoxical reactions can reveal diagnostic clues and should be documented for future care.
Use the least medication necessary, but prioritize efficacy
- Abrams prefers minimalism when possible.
- But he will not reduce medications at the expense of symptom control or safety.
- Shared decision-making is key, especially when balancing benefit against long-term risks.
Bottom Line
Dr. Abrams presents a psychiatry framework that is broader than neurotransmitters alone. His core message is that mental health is deeply shaped by endocrine systems, sleep, stress physiology, and life context—and that effective treatment often requires treating the whole person, not just “the diagnosis.” He also underscores that psychiatric medications can be highly effective, but they are not always enough, and the future of the field may lie in integrating psychopharmacology with endocrinology, neurobiology, and more personalized care.